Abzu vs Adaptyv Biosystems

<p>Abzu is a biotechnology software platform that leverages artificial intelligence to develop advanced RNA therapies such as siRNAs, ASOs, and anti-miRs for major medical needs. It integrates deep RNA biology knowledge with AI-driven design and drug development expertise, enabling you to explore and prioritize vast RNA sequence variants computationally. This reduces experimental costs, shortens candidate selection time, and improves overall drug design efficiency.</p> <p>The platform also supports targeted RNA delivery by developing programmable aptamers for cell-specific uptake, creating a modular system for precision beyond traditional liver-focused delivery. Abzu serves biotech researchers and pharmaceutical teams aiming to innovate RNA drug development, offering case studies and AI models that enhance therapeutic design safety and efficacy. While currently fundraising, Abzu emphasizes explainable AI to boost pharma trust and streamline workflows.</p>

<p>Adaptyv Biosystems provides an all-in-one software platform for protein designers to order, manage, and analyze experimental protein data efficiently. It streamlines your research process by allowing you to upload protein sequences securely, run automated lab experiments, and receive clean, high-quality data packages in just three weeks. Designed for AI-first protein engineering, it integrates experimental results directly into your generative AI workflows to help you create novel proteins tailored to your needs.</p> <p>With Adaptyv, you can manage all wet lab experiments from a single interface, track progress with real-time updates, and analyze results without juggling spreadsheets. Its comprehensive API ensures seamless integration into your existing research systems. Whether you focus on binding affinity, expression levels, or functional protein characteristics, Adaptyv accelerates your design-build-test cycle with transparent pricing and robust automation, empowering you to improve your protein designs continuously.</p>